Advertisement

Variation in receipt of therapy and survival with provider volume for medical oncology in non-curative esophago-gastric cancer: a population-based analysis

  • Julie HalletEmail author
  • Laura E. Davis
  • Alyson L. Mahar
  • Ying Liu
  • Victoria Zuk
  • Vaibhav Gupta
  • Craig C. Earle
  • Natalie G. Coburn
Original Article

Abstract

Background

While surgical care by high-volume providers for esophago-gastric cancer (EGC) yields better outcomes, volume–outcome relationships are unknown for systemic therapy. We examined receipt of therapy and outcomes in the non-curative management of EGC based on medical oncology provider volume.

Methods

We conducted a population based retrospective cohort study of non-curative EGC over 2005–2017 by linking administrative healthcare datasets. The volume of new EGC consultations per medical oncology provider per year was calculated and divided into quintiles. High-volume (HV) medical oncologists were defined as the 4–5th quintiles. Outcomes were receipt of chemotherapy and overall survival (OS). Multivariate logistic and Cox-proportional hazards regressions examined the association between management by HV medical oncologist, receipt of systemic therapy, and OS.

Results

7011 EGC patients with non-curative management consulted with medical oncology. 1-year OS was superior for HV medical oncologists (> 11 patients/year), with 28.4% (95% CI 26.7–30.2%) compared to 25.1% (95% CI 23.8–26.3%) for low volume (p < 0.001). After adjusting for age, sex, comorbidity burden, rurality, income quintile, and diagnosis year, HV medical oncologist was independently associated with higher odds of receiving chemotherapy (OR 1.13, 95% CI 1.01–1.26), and independently associated with superior OS (HR 0.89, 95% CI 0.84–0.93).

Conclusions

Medical oncology provider volume was associated with variation in non-curative management and outcomes of EGC. Care by an HV medical oncologist was independently associated with higher odds of receiving chemotherapy and superior OS, after adjusting for case mix. This information is important to inform disease care pathways and care organization; an increase in the number of HV medical oncologists may reduce variation and improve outcomes.

Keywords

Esophagus Stomach Cancer Outcomes Volume 

Notes

Acknowledgements

This study was supported by the Canadian Institute of Health Research (FRN #154131) and the Sherif and Mary-Lou Hanna Chair in Surgical Oncology Research. This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. Parts of this material are based on data and information compiled and provided by CIHI. However, the analyses, conclusions, opinions, and statements expressed herein are those of the author, and not necessarily those of CIHI. Parts of this material are based on data and information provided by Cancer Care Ontario (CCO). The opinions, results, view, and conclusions reported in this paper are those of the authors and do not necessarily reflect those of CCO. No endorsement by CCO is intended or should be inferred.

Funding

This study was supported by the Canadian Institute of Health Research (FRN #154131).

Compliance with ethical standards

Conflict of interest

Julie Hallet has received speaking honoraria from Ipsen Biopharmaceuticals Canada and Novartis Oncology. Natalie Coburn receives salary support from Cancer Care Ontario as the Clinical Lead of Patient Reported Outcomes and Symptom Management. Laura Davis declares that she has not conflict of interest. Alyson Mahar declares that she has not conflict of interest. Ying Liu declares that she has not conflict of interest. Vaihbav Gupta declares that he has not conflict of interest. Craig Earle declares that he has not conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was waived by the Sunnybrook Health Sciences Centre Research Ethics Board, for the conduct of population-based analysis.

Supplementary material

10120_2019_1012_MOESM1_ESM.pdf (243 kb)
Supplementary file1 (PDF 243 kb)

References

  1. 1.
    Bilimoria KY, Bentrem DJ, Feinglass JM, Stewart AK, Winchester DP, Talamonti MS, et al. Directing surgical quality improvement initiatives: comparison of perioperative mortality and long-term survival for cancer surgery. J Clin Oncol. 2008;26:4626–33.PubMedCrossRefGoogle Scholar
  2. 2.
    Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349:2117–27.PubMedCrossRefGoogle Scholar
  3. 3.
    Birkmeyer JD, Siewers AE, Marth NJ, Goodman DC. Regionalization of high-risk surgery and implications for patient travel times. JAMA. 2003;290:2703–8.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Simunovic M, Urbach D, Major D, Sutradhar R, Baxter N, To T, et al. Assessing the volume-outcome hypothesis and region-level quality improvement interventions: pancreas cancer surgery in two Canadian Provinces. Ann Surg Oncol. 2010;17:2537–44.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Gasper WJ, Glidden DV, Jin C, Way LW, Patti MG. Has recognition of the relationship between mortality rates and hospital volume for major cancer surgery in California made a difference?: a follow-up analysis of another decade. Ann Surg. 2009;250:472–83.PubMedGoogle Scholar
  6. 6.
    Dikken JL, Dassen AE, Lemmens VEP, Putter H, Krijnen P, van der Geest L, et al. Effect of hospital volume on postoperative mortality and survival after oesophageal and gastric cancer surgery in the Netherlands between 1989 and 2009. Eur J Cancer. 2012;48:1004–133.PubMedCrossRefGoogle Scholar
  7. 7.
    Fischer C, Lingsma H, Klazinga N, Hardwick R, Cromwell D, Steyerberg E, et al. Volume-outcome revisited: the effect of hospital and surgeon volumes on multiple outcome measures in oesophago-gastric cancer surgery. PLoS ONE. 2017;12:e0183955.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Ireland C, Wiedower E, Mirza M, Crawley M, Tran A, Yaghmour G, et al. Impact of provider volume on outcomes of patients with hodgkin lymphoma. World J Oncol. 2018;9:46–9.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Huntington SF, Hoag JR, Zhu W, Wang R, Zeidan AM, Giri S, et al. Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma. Cancer. 2018;64:786–4220.Google Scholar
  10. 10.
    Go RS, Bartley AC, Crowson CS, Shah ND, Habermann EB, Holton SJ, et al. Association between treatment facility volume and mortality of patients with multiple myeloma. J Clin Oncol. 2017;35:598–604.PubMedCrossRefGoogle Scholar
  11. 11.
    Go RS, Al-Hamadani M, Shah ND, Crowson CS, Holton SJ, Habermann EB. Influence of the treatment facility volume on the survival of patients with non-Hodgkin lymphoma. Cancer. 2016;122:2552–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Shanafelt TD, Kay NE, Rabe KG, Inwards DJ, Zent CS, Leis JF, et al. Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Cancer. 2012;118:1827–37.PubMedCrossRefGoogle Scholar
  13. 13.
    Institute of Medicine (US), and National Research Council (US) National Cancer Policy Board, Hewitt M, Petitti D. Interpreting the volume–outcome relationship in the context of cancer care. Washington (DC): National Academies Press; 2001.Google Scholar
  14. 14.
    Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, Lami Al FH, Alam T, Alizadeh-Navaei R, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2018;4:1553–688.CrossRefGoogle Scholar
  15. 15.
    Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v38–v49.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS SSO and TOS. Ann Oncol. 2018;30:19–33.CrossRefGoogle Scholar
  17. 17.
    Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, et al. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw. 2015;13:194–227.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Mackenzie M, Spithoff K, Jonker D, Gastrointestinal Disease Sity Group. Systemic therapy for advanced gastric cancer: a clinical practice guideline. Curr. Oncol. 2011;18:e202–e209209.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRefGoogle Scholar
  21. 21.
    Canada GO, Canada H, Branch SP, Division CHA. Canada Health Act—Health Care System—Health Canada. https://www.hc-sc.gc.ca/hcs-sss/medi-assur/cha-lcs/index-eng.php.
  22. 22.
    Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015;12:e1001885–e10019221001922.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Robles SC, Marrett LD, Clarke EA, Risch HA. An application of capture-recapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol. 1988;41:495–501.PubMedCrossRefGoogle Scholar
  24. 24.
    Iron K, Zagorski BM, Sykora K, Manuel DG. Living and dying in Ontario: an opportunity for improved health information. ICES Investigative Report. Toronto: Institute for Clinical Evaluative Sciences; 2008.Google Scholar
  25. 25.
    Booth CM, Nanji S, Wei X, Peng Y, Biagi JJ, Hanna TP, et al. Use and effectiveness of adjuvant chemotherapy for stage III colon cancer: a population-based study. J Natl Compr Canc Netw. 2016;14:47–56.PubMedCrossRefGoogle Scholar
  26. 26.
    Nam RK, Cheung P, Herschorn S, Saskin R, Su J, Klotz LH, et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncol. 2014;15:223–31.PubMedCrossRefGoogle Scholar
  27. 27.
    Rabeneck L, Paszat LF, Rothwell DM, He J. Temporal trends in new diagnoses of colorectal cancer with obstruction, perforation, or emergency admission in Ontario: 1993–2001. Am J Gastroenterol. 2005;100:672–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Kagedan DJ, Abraham L, Goyert N, Li Q, Paszat LF, Kiss A, et al. Beyond the dollar: Influence of sociodemographic marginalization on surgical resection, adjuvant therapy, and survival in patients with pancreatic cancer. Cancer. 2016;122:3175–82.PubMedCrossRefGoogle Scholar
  29. 29.
    Karlj B. Measuring, “rurality” for purposes of health-care planning: an empirical measure for Ontario. Ont Med Rev. 2009;67:33–52.Google Scholar
  30. 30.
    Alter DA, Naylor CD, Austin P, Tu JV. Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med. 1999;341:1359–67.PubMedCrossRefGoogle Scholar
  31. 31.
    Wilkins R. Use of postal codes and addresses in the analysis of health data. Health Rep. 1993;5:157–77.PubMedGoogle Scholar
  32. 32.
    Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8–27.PubMedCrossRefGoogle Scholar
  33. 33.
    Gutacker N, Bloor K, Cookson R. Comparing the performance of the Charlson/Deyo and Elixhauser comorbidity measures across five European countries and three conditions. Eur J Public Health. 2015;25(Suppl 1):15–20.PubMedCrossRefGoogle Scholar
  34. 34.
    Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc. 2012;6:128–32.Google Scholar
  35. 35.
    Gastwirth JL, Gel YR, Miao W. The impact of Levene’s test of equality of variances on statistical theory and practice. Stat Sci. 2009;24:343–60.CrossRefGoogle Scholar
  36. 36.
    Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health. 1989;79:340–9.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Robins JM, Greenland S. The role of model selection in causal inference from nonexperimental data. Am J Epidemiol. 1986;123:392–402.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Abrams TA, Brightly R, Mao J, Kirkner G, Meyerhardt JA, Schrag D, et al. Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer. J Clin Oncol. 2011;29:3255–62.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Okines AFC, Norman AR, McCloud P, Kang Y-K, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 2009;20:1529–34.PubMedCrossRefGoogle Scholar
  41. 41.
    Wennberg JE. Unwarranted variations in healthcare delivery: implications for academic medical centres. BMJ. 2002;325:961–4.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Goodman DC. Unwarranted variation in pediatric medical care. Pediatr Clin N Am. 2009;56:745–55.CrossRefGoogle Scholar
  43. 43.
    Mercuri M, Gafni A. Medical practice variations: what the literature tells us (or does not) about what are warranted and unwarranted variations. J Eval Clin Pract. 2011;17:671–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Sepucha K, Ozanne E, Mulley AG. Doing the right thing: systems support for decision quality in cancer care. Ann Behav Med. 2006;32:172–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med. 2002;137:511–20.PubMedCrossRefGoogle Scholar
  46. 46.
    Thiemann DR, Coresh J, Oetgen WJ, Powe NR. The association between hospital volume and survival after acute myocardial infarction in elderly patients. N Engl J Med. 1999;340:1640–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Adams EK, Wright GE. Hospital choice of Medicare beneficiaries in a rural market: why not the closest? J Rural Health. 1991;7:134–52.PubMedCrossRefGoogle Scholar
  48. 48.
    Melnychuk M, Vindrola-Padros C, Aitchison M, Clarke CS, Fulop NJ, Levermore C, et al. Centralising specialist cancer surgery services in England: survey of factors that matter to patients and carers and health professionals. BMC Cancer. 2018;18:226.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Loberiza FR, Cannon AJ, Weisenburger DD, Vose JM, Moehr MJ, Bast MA, et al. Survival disparities in patients with lymphoma according to place of residence and treatment provider: a population-based study. J Clin Oncol. 2009;27:5376–82.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Berry SR, Bell CM, Ubel PA, Evans WK, Nadler E, Strevel EL, et al. Continental divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. J Clin Oncol. 2010;28:4149–53.PubMedCrossRefGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2019

Authors and Affiliations

  • Julie Hallet
    • 1
    • 2
    • 3
    • 4
    Email author
  • Laura E. Davis
    • 3
  • Alyson L. Mahar
    • 5
  • Ying Liu
    • 4
  • Victoria Zuk
    • 3
  • Vaibhav Gupta
    • 2
  • Craig C. Earle
    • 4
    • 6
  • Natalie G. Coburn
    • 1
    • 2
    • 3
    • 4
  1. 1.Division of Surgical OncologyOdette Cancer Centre-Sunnybrook Health Sciences CentreTorontoCanada
  2. 2.Department of SurgeryUniversity of TorontoTorontoCanada
  3. 3.Sunnybrook Research InstituteTorontoCanada
  4. 4.ICESTorontoCanada
  5. 5.Department of Community Health SciencesUniversity of ManitobaWinnipegCanada
  6. 6.Division of Medical OncologyOdette Cancer Centre-Sunnybrook Health Sciences CentreTorontoCanada

Personalised recommendations